BioSpace News Archive

In the midst of the COVID-19 pandemic, healthcare workers across the world have been active on social media displaying the painful results of wearing medical personal protective equipment for long hours on the job.

Mesoblast Limited announced that its allogeneic mesenchymal stem cell product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome caused by coronavirus infection.

Correvio Pharma Corp. announced that it has obtained an interim order from the Supreme Court of British Columbia authorizing the holding of an annual general and special meeting of the Securityholders and matters relating to the conduct of the Meeting.

Talentum Engineering Services (TES) announced this week their solution to the increasing need for rapid and safe COVID-19 symptom screening. The San Antonio based company, which specializes in customized technology solutions, developed the Workplace Screening System (WS2).

An ongoing quantitative survey conducted by Continuum Clinical in partnership with the Association of Clinical Research Professionals (ACRP) shows 31% of clinical research study sites fear total closure as COVID-19-related stay-at-home orders and patient concerns over interacting with healthcare professionals continue to increase.

At the tenth virtual meeting of an ad hoc committee on combating COVID-19 in affected countries, headed by the Supervisor General of the King Salman Humanitarian Aid and Relief Centre, Dr. Abdullah Al Rabeeah, six new contracts were signed with specialized companies to provide medical support to Yemen and Palestine to combat the COVID-19 pandemic.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced today the filing of its Form 15 certifying that it has less than 300 stockholders of record and deregistering its Common Stock under Section 12(g) of the Securities Exchange Act of 1934,

Vivera Pharmaceuticals, Inc., a California based pharmaceutical company, is beginning to distribute its COVID-19 point of care rapid serological test.

The U.S. Food and Drug Administration announced the following actions taken as part of its ongoing response to the COVID-19 pandemic

Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced topline results from the interim analysis of its ongoing clinical Phase II study evaluating STP705 for treatment of non-melanoma skin cancer, specifically squamous cell carcinoma in situ (isSCC).